GENB:NASDAQ, Generate Biomedicines Inc.

Why GENB stock fell on November 16

Generate Biomedicines Inc. fell 13.1% on Monday, November 16, 2026, on 1,316,300 shares. The headline around the move:

GENB stock overview

Generate Biomedicines Inc. (GENB:NASDAQ) closed at $9.54 on November 20, 2026, down 8.00% on the day. The stock trades 57.9% below its 52-week high of $22.67 and 1.5% above its 52-week low of $9.40. Over the past year, it lost 24.6%. Generate Biomedicines Inc. is part of the Health Care sector.

Key figures

Price
$9.54
Day change
-8.00%
Volume
967,195
Average volume
1,237,267
Market cap
1B+
52-week range
$9.40 – $22.67
50-day average
$13.91
200-day average
$13.95

Price action over the past year

In 185 trading sessions since March 2, 2026, GENB closed higher on 90 days (49%). Its best day was October 28, 2026 (+16.43%) and its worst was August 26, 2026 (-20.80%). The stock moved 10% or more in a single session 13 times.

Recent signals

GENB news

About Generate Biomedicines Inc.

Generate Biomedicines is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. Our vision is to program biology to generate optimal therapeutics for the greatest impact on human health. Central to our vision is the Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. We have built our Generate Platform to be a tight and fully-integrated loop (design-build-test-learn) to create proprietary, therapeutically relevant data and differentiated molecular solutions for the biological challenges we aim to address.

Similar stocks

Find more stocks like GENB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.